Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 391

Sort by

Sort Order Select

Journal Articles

A New Step in Understanding of Fanconi Patients Peripheral Stem Cell Harvesting, a Bridge to Gene Therapy

Jean-Sebastien Diana, MD, Sandra Manceau, PhD, Thierry Leblanc, MD, Chloé Couzin, MD, Alessandra Magnani, MD PhD, Elisa Magrin, PhD, Matthieux Bendavid, MD, Laure Joseph, MD, Marianne Delville, MD, Stephane Blanche, MD, Jean Soulier, MD PhD, Marina Cavazzana, MD PhD, Francois Lefrere, MD

Blood (2019) 134 (Supplement_1): 1970.

https://doi.org/10.1182/blood-2019-128051

Published: 2019

Journal Articles

Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM

Blood (2019) 134 (Supplement_1): 1949.

https://doi.org/10.1182/blood-2019-131546

Published: 2019

Journal Articles

Safe and Efficient Peripheral Blood Stem Cell Collection in Patients with Sickle Cell Disease Using Plerixafor

Alexis Leonard, MD, Naoya Uchida, MD, David F. Stroncek, MD, Sandhya R. Panch, MDMPH, Kamille West, Eoghan George Molloy, MD, Tom Hughes, Pharm.D., Sara Hauffe, RN, Tiffani Taylor, Courtney D. Fitzhugh, MD, Jane S. Hankins, MD MS, Megan Wilson, MSW, CCRP, Akshay Sharma, MBBS, Shengdar Q. Tsai, PhD, Mitchell J. Weiss, MD, PhD, Matthew Hsieh, MD, John F. Tisdale, MD

Blood (2019) 134 (Supplement_1): 1964.

https://doi.org/10.1182/blood-2019-126091

Published: 2019

Journal Articles

Ofatumumab Plus Hypercvad/MA Induction Leads to High Rates of Minimal Residual Disease (MRD) Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma, Results of a Phase 2 Study

Pallawi Torka, MD, Nishitha Reddy, MD, Adrienne Groman, MS, Angela Kader, Jenna Nichols, Alan Hutson, Cory Mavis, MSc, Joseph Dennis Tario, PhD, Paul K. Wallace, MS, PhD, AnneMarie W. Block, PhD, Sheila N. J. Sait, PhD, Bora E Baysal, MD PhD, Vishala T. Neppalli, MD, Suchitra Sundaram, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 2817.

https://doi.org/10.1182/blood-2019-123488

Published: 2019

Journal Articles

Feasibility of Peripheral Blood Stem Cell Collection from Heterozygoussickle Cell Trait Donors

Juergen Foell, MD, Morad Morez, Anja Troeger, MD, Katharina Kleinschmidt, MD PhD, Beatrix Pfirstinger, Andreas Brosig, MD PhD, Ralph Burkhardt, MD PhD, Selim Corbacioglu, MD, Norbert Ahrens

Blood (2019) 134 (Supplement_1): 1171.

https://doi.org/10.1182/blood-2019-131984

Published: 2019

Journal Articles

Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Blood (2019) 134 (Supplement_1): 864.

https://doi.org/10.1182/blood-2019-131476

Published: 2019

Journal Articles

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study

Blood (2019) 134 (Supplement_1): 862.

https://doi.org/10.1182/blood-2019-126378

Published: 2019

Journal Articles

Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma

Abdullah S. Al Saleh, MBBS, M Hasib Sidiqi, MBBS, Morie A. Gertz, MD, Eli Muchtar, MD, Martha Q. Lacy, MD, Rahma M Warsame, MD, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, William J Hogan, MB, BCh, Suzanne R. Hayman, MD, Prashant Kapoor, MD, Francis K. Buadi, MB, CHB, Angela Dispenzieri, MD, David Dingli, MD PhD, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 4505.

https://doi.org/10.1182/blood-2019-131380

Published: 2019

Journal Articles

Historical Analysis of a Cohort of Chilean Patients Treated with Autologous Stem Cell Transplantation Since 1993: Optimization of Stem Cell Collections, Risk Factors for Poor Mobilizers and Efficient Plerixafor Use

Mauricio Sarmiento Maldonado, MD, Jara Veronica, Silvana Arellano, Soto Katherine, Carla Lorca, Isabel Pizarro, Pablo Bertin, MD, Mauricio Galleguillos, Elizabeth Rivera, Isabel Rodriguez, Nicole Beffermann, Mauricio Ocqueteau, MD, Jaime Pereira, MD

Blood (2019) 134 (Supplement_1): 5641.

https://doi.org/10.1182/blood-2019-124328

Published: 2019

Journal Articles

Impact of Neurocognitive Dysfunction in a Veteran Population Undergoing First Outpatient Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Shakira J. Grant, MBBS, Lindsay M. Hannan, MD MSPH, Jessica L. Brand, PhD, Robert E. Richard, MD PhD, Daniel Y. Wu, MD, Solomon A. Graf, MD, Jonathan Grim, MD PhD, Nicholas Burwick, MD, Thomas R. Chauncey, MD PhD

Blood (2019) 134 (Supplement_1): 5883.

https://doi.org/10.1182/blood-2019-122580

Published: 2019

Journal Articles

Age Matters: Younger Unrelated PBSC Donors Experience Less G-CSF-Related Symptoms and Have a Faster Emotional Recovery Than Older Donors

Jose ROS Soto, MBBS, Eva Zoubek, PhD, Richard Szydlo, PhD, Paul Johnson, Ann O'Leary, Maria Del Mar Cuadrado, MBBS, Catherine Burlton, J. Alejandro Madrigal, MDPhDDSc,FRCP,FRCPath, Chloe Anthias, MD

Blood (2019) 134 (Supplement_1): 3249.

https://doi.org/10.1182/blood-2019-122304

Published: 2019

Journal Articles

Autologous Stem Cell Transfusions on Multiple Days in Patients with Multiple Myeloma - Does It Matter?

Thomas Pabst, MD, Sebastian Moser, Ulrike Bacher, Barbara Jeker, Behrouz Mansouri Taleghani, Prof., Urban Novak

Blood (2019) 134 (Supplement_1): 3252.

https://doi.org/10.1182/blood-2019-127940

Published: 2019

Journal Articles

A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy

J Christine Ye, MDMSc, Philip S Boonstra, PhD, Daniel F. Boyer, MD PhD, Larry D. Anderson, MD PhD, Brea C. Lipe, MD, Andrew Kin, MD, Erica L. Campagnaro, MD, Matthew J. Pianko, MD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 3191.

https://doi.org/10.1182/blood-2019-132204

Published: 2019

Journal Articles

Real-World Outcomes of Ixazomib in the Treatment of Multiple Myeloma from a Single Center in China

Weiwei Sui, Gang An, Shuhui Deng, MD, Yan Xu, Mu Hao, Fu Mingwei, Tingyu Wang, Shuhua Yi, MD, Yaozhong Zhao, Dehui Zou, MD, Zengjun Li, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 5581.

https://doi.org/10.1182/blood-2019-126718

Published: 2019

Journal Articles

Safety and Efficacy of Venetoclax Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide Chemoimmunotherapy (VICER) for Treatment of Relapsed Diffuse Large B Cell Lymphoma: Results from the Phase 1 Study

Paolo Caimi, MD, Deepa Jagadeesh, MDMPH, Kirsten Marie Boughan, DO, Robert M. Dean, MD, Brenda Cooper, MD, Brad Pohlman, MD, Molly M Gallogly, MDPhD, Sarah L. Ondrejka, DO, Erika Moore, MD, Kwadwo Asare Oduro, MDPhD, Eric D. Hsi, MD, Marcos de Lima, MD, Brian T. Hill, MD PhD

Blood (2018) 132 (Supplement 1): 397.

https://doi.org/10.1182/blood-2018-99-115587

Published: 2018

Journal Articles

One-Day Low-Dose Etoposide Is an Effective Chemomobilization Regimen with Minimal Toxicity for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Multicenter Study from Tertiary Hospitals in Korea

Yong Park, MD, Dae Sik Kim, MD PhD, Ka-Won Kang, MD, Byung-Hyun Lee, MD, Eun Sang Yu, MD, Min Ji Jeon, MD, Hojoon Choi, MD, Se Ryeon Lee, MD PhD, Hwa Jung Sung, MD PhD, Chul Won Choi, MD PhD, Kihyun Kim, MD PhD, Byung Soo Kim, MD PhD, Seok Jin Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3347.

https://doi.org/10.1182/blood-2018-99-115625

Published: 2018

Journal Articles

Evaluation of Pre-Collection Factors and Collection Efficiency Leads to Strong Correlation between Predicted and Actual Peripheral Blood Stem Cell Collection Yields in Multiple Myeloma Patients: A Single Institution Experience

FEI FEI, MD, Daniel Peavey, Mariam Youssef, MD, Sondra Dunn, RN, Terry Slover, RN, Nick Boshell, RN, Marisa B. Marques, MD, Luciano J Costa, MD PhD, X. Long Zheng, MD PhD, Lance Williams, MD

Blood (2018) 132 (Supplement 1): 3349.

https://doi.org/10.1182/blood-2018-99-117320

Published: 2018

Journal Articles

Metabolomics Profiling after Allogeneic Hematopoietic Stem Cell Transplantation Unravels a Specific Signature in Human Acute GVHD

David Michonneau, MD, Eleonora Latis, Laetitia Dubouchet, Regis Peffault De Latour, Marie Robin, MD PhD, Flore Sicre De Fontbrune, MD PhD, Lars Rogge, PhD, Gerard Socie, MD PhD

Blood (2018) 132 (Supplement 1): 69.

https://doi.org/10.1182/blood-2018-99-110441

Published: 2018

Journal Articles

Randomized Trials of Autologous Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Systematic Review and Meta-Analysis with Trial Sequential Analysis of Overall Mortality

Amit Patel, MBBS, PhD MRCP(Lond), MRCS(Eng), MAcadMEd, FFICM, FRCPath, Yeong Jer Lim, MBChB, MRCP(UK)

Blood (2018) 132 (Supplement 1): 612.

https://doi.org/10.1182/blood-2018-99-115326

Published: 2018

Journal Articles

Does Use of Biosimilar G-CSF Change Plerixafor Utilization during Stem Cell Mobilization for Autologous Stem Cell Transplant?

Nadine Abdallah, MD, Seongho Kim, PhD, Asif Alavi, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2018) 132 (Supplement 1): 4557.

https://doi.org/10.1182/blood-2018-99-118400

Published: 2018

NARROW

A New Step in Understanding of Fanconi Patients Peripheral Stem Cell Harvesting, a Bridge to Gene Therapy

Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM

Safe and Efficient Peripheral Blood Stem Cell Collection in Patients with Sickle Cell Disease Using Plerixafor

Ofatumumab Plus Hypercvad/MA Induction Leads to High Rates of Minimal Residual Disease (MRD) Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma, Results of a Phase 2 Study

Feasibility of Peripheral Blood Stem Cell Collection from Heterozygoussickle Cell Trait Donors

Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study

Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma

Historical Analysis of a Cohort of Chilean Patients Treated with Autologous Stem Cell Transplantation Since 1993: Optimization of Stem Cell Collections, Risk Factors for Poor Mobilizers and Efficient Plerixafor Use

Impact of Neurocognitive Dysfunction in a Veteran Population Undergoing First Outpatient Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Age Matters: Younger Unrelated PBSC Donors Experience Less G-CSF-Related Symptoms and Have a Faster Emotional Recovery Than Older Donors

Autologous Stem Cell Transfusions on Multiple Days in Patients with Multiple Myeloma - Does It Matter?

A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy

Real-World Outcomes of Ixazomib in the Treatment of Multiple Myeloma from a Single Center in China

Safety and Efficacy of Venetoclax Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide Chemoimmunotherapy (VICER) for Treatment of Relapsed Diffuse Large B Cell Lymphoma: Results from the Phase 1 Study

One-Day Low-Dose Etoposide Is an Effective Chemomobilization Regimen with Minimal Toxicity for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Multicenter Study from Tertiary Hospitals in Korea

Evaluation of Pre-Collection Factors and Collection Efficiency Leads to Strong Correlation between Predicted and Actual Peripheral Blood Stem Cell Collection Yields in Multiple Myeloma Patients: A Single Institution Experience

Metabolomics Profiling after Allogeneic Hematopoietic Stem Cell Transplantation Unravels a Specific Signature in Human Acute GVHD

Randomized Trials of Autologous Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Systematic Review and Meta-Analysis with Trial Sequential Analysis of Overall Mortality

Does Use of Biosimilar G-CSF Change Plerixafor Utilization during Stem Cell Mobilization for Autologous Stem Cell Transplant?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only